Reports
Showing 41–60 of 83 results
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Lucentis (ranibizumab)€ 300.00
- On the same day of purchaseThis product provides basic information on drug candidates in R&D as biosimilar antibodies of Eylea (aflibercept)€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D as biosimilar antibodies of Stelara (ustekinumab).€ 300.00
- On the same day of purchaseThis product provides basic information on approved drugs and drug candidates in R&D targeting thymic stromal lymphopoietin (TSLP) or its receptor (TSLP-R).€ 300.00
- March of 2023Sales data of originator therapeutic proteins and antibodies & selected biosimilar antibodies and proteins and other biologics in 2022€ 120.00
- February of 2023Antibody Target, Technology & Pipeline Database€ 1600.00
- February of 2023This report provides a landscape description and analysis of CAR-M platform technologies and stakeholders from an industry perspective as of February 2023€ 1800.00
- November of 2022This report provides a landscape description and analysis of discovery and development of novel drug modalities targeting RNA from an industry perspective as of November 2019.€ 2350.00
- July of 2022This report bundle includes four reports about novel cancer targets which have in common a compelling target expression profile with a low risk of on-target/off-tumor toxicity.€ 1800.00
- July of 2022The report evaluates opportunities for GPRC5D-targeted drug modalities within the competitive landscape.€ 600.00
- June of 2022The report evaluates opportunities for ROR1-targeted drug modalities within the competitive landscape€ 1050.00
- May of 2022This report describes and analyzes cadherin 17 (CDH17) as a target opportunity for development of effector-enhanced drug modalities€ 400.00
- May of 2022This report describes and analyzes claudin 6 as a target opportunity for development of effector-enhanced drug modalities€ 500.00
- March of 2022This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2021€ 100.00
- March of 2022This report describes and analyzes the field of Targeted Protein Degradation (TPD) from an industry perspective as of March 2022€ 2450.00
- July and October of 2021Package of two reports with emerging evolutionary technologies of Vectorized Antibodies and Prodrug Antibodies & Cytokines€ 2200.00
- October of 2021Landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technologies from an industry perspective as of October 2021€ 2250.00
- July of 2021This report provides you with a landscape description and analysis of direct in vivo delivery of nucleic acid-encoded antibodies employing DNA and mRNA platform technologies from an industry perspective as...€ 2150.00
- March of 2021Compilation of the global sales data of branded originator recombinant therapeutic proteins and antibodies, of selected biosimilars and other novel biologics in the calendar year 2020€ 100.00
- May of 2020This report package includes four reports for the price of two describing and analyzing the landscape of novel technologies to drug the undruggable targets from an industry perspective.€ 4125.00